On Oct. 21, 2020, results from an international, randomized, controlled clinical trial indicated that a four-month daily treatment regimen containing high-dose, or ﾓoptimized,ﾔ rifapentine with moxifloxacin is as safe and effective as the existing standard six-month daily regimen at curing drug-susceptible tuberculosis (TB) disease. This regimen is the first successful short-course treatment regimen for drug-susceptible TB disease in almost 40 years.

According to recent WHO estimates, 10 million new TB cases and 1.4 million deaths from TB occurred globally in 2019. The U.S. reported nearly 10,000 cases of TB.